Interim data for CBAY... "After sharing preliminary results from the study, the FDA has agreed to allow continuation of seladelpar treatment beyond six months for the 5 mg and 10 mg doses."

Keep this in mind when we see our interim data for prurisol.

https://finance.yahoo.com/news/cymabay-announ...00760.html